PharmiWeb.com - Global Pharma News & Resources
23-Jan-2019

Global Insulinoma Treatment Market Analysis & Outlook 2019-2023; Led by Ipsen Pharma, Johnson & Johnson, Novartis, Pfizer, and Teva Pharmaceutical Industries - ResearchAndMarkets.com

The "Global Insulinoma Treatment Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

The insulinoma treatment market will register a CAGR of over 4% by 2023.

Advances in laparoscopic treatment and diagnostic techniques have a considerable impact on the global insulinoma treatment market. This high cost of treatment, however, is a major challenge to the treatment of insulinoma, thus reducing patient adherence.

Many government and non-government organizations, including companies are focusing on providing funding and grants as well as clinical assistance of ten treatment of various neuroendocrine tumors. Such funding programs encourage more patients to avail the treatment, which, in turn, increase the patient base. Such programs help patients adhere to the treatment regimen, even it is a long- term procedure.

Advanced diagnostic techniques

Insulinoma is one of the key segments of the neuroendocrine tumors. Therefore, such advance in the field of diagnosis of neuroendocrine tumors will have a positive impact on the global insulinoma treatment market.

Shortage of patients volunteering of clinical trails

Numerous patients volunteer to participate in clinical trails, which has led to many innovations in disease prevention and treatment over the years. Without the willingness of the participating patients, many other people would have suffered with disease.

Key Players

  • Ipsen Pharma
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • Teva Pharmaceutical Industries

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

PART 04: MARKET SIZING

PART 05: FIVE FORCES ANALYSIS

PART 06: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Surgery - Market size and forecast 2018-2023
  • Drugs - Market size and forecast 2018-2023
  • Other treatments - Market size and forecast 2018-2023
  • Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DRIVERS AND CHALLENGES

PART 10: MARKET TRENDS

PART 11: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 12: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Ipsen Pharma
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • Teva Pharmaceutical Industries

For more information about this report visit https://www.researchandmarkets.com/research/lwnzxn/global_insulinoma?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20190123005410/en/

Editor Details

Last Updated: 23-Jan-2019